Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES)

Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES) focus is on the treatment of diabetes and related metabolic disorders. They have a pipeline of innovative oral product candidates that are supported by issued and filed U.S. patents. Their product candidates are proven to lower and control blood glucose levels in patients with Type 2 diabetes. With approximately 20 million people suffering from diabetes in the U.S. alone, blood sugar control via oral drugs represents a multi-billion dollar market opportunity. For further information, visit the Company’s web site at www.akesis.com.